➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,629,852

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,629,852 protect, and when does it expire?

Patent 9,629,852 protects XELPROS and is included in one NDA.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 9,629,852
Title:Ophthalmic composition comprising a prostaglandin
Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Inventor(s): Khopade; Ajay Jaysingh (Baroda, IN), Halder; Arindam (Baroda, IN), Bhowmick; Subhas Balaram (Baroda, IN)
Application Number:12/601,429
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,629,852
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,629,852

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharma Global XELPROS latanoprost EMULSION;OPHTHALMIC 206185-001 Sep 12, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,629,852

PCT Information
PCT FiledOctober 15, 2008PCT Application Number:PCT/IN2008/000671
PCT Publication Date:July 09, 2009PCT Publication Number: WO2009/084021

International Family Members for US Patent 9,629,852

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008344909   Start Trial
Brazil PI0818459   Start Trial
Canada 2702478   Start Trial
China 101835473   Start Trial
Colombia 6270384   Start Trial
Eurasian Patent Organization 201070483   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.